Ashok Leyland share pros and cons: India’s 2nd-largest CV maker and bus market leader analysed for 2026. Switch EV ambition, bus dominance, CV cyclicality, and debt risks covered.

Abans Financial Services share price target 2027 is Rs 285 (+42%), 2028 is Rs 325 (+62%), and 2030 is Rs 430 (+114%). Financial Services stock long term analyst

MRF share pros and cons: India’s largest tyre company at Rs 1.34 lakh share price analysed for 2026. Market leadership, brand equity, rubber cost risks, and high face value accessibility limitation covered.

Stock market today on 7 August 2026: Nifty 50 opens at 24,538.90 (-0.21%), Sensex at 78,516 (-0.42%), Nifty Bank -0.29%. India VIX rises 1.40% to 12.33. SBI Q1 results today.

SRF share pros and cons: India’s specialty chemicals leader with fluorine chemistry moat analysed for 2026. Agrochemical tailwind, China Plus One benefit, refrigerant transition, and cyclicality risks covered.

Torrent Pharmaceuticals share pros and cons: branded generics quality franchise analysed for 2026. Germany market leadership, India chronic care dominance, 89x PE risk, and Mehta family discipline covered.

Why HAL share price keeps rising: LCA Tejas Mk1A Rs 48,000 crore order, 90,000+ crore order book, defence indigenisation, growing MRO revenue and India’s rising defence budget. Full analysis.

Why Cupid share price is rising: government contraceptive tenders, UNFPA and WHO export orders, branded consumer growth and capacity expansion. Full fundamental analysis of Cupid Ltd.

Mankind Pharma share pros and cons: India domestic pharma volume leader analysed for 2026. Rural doctor penetration, consumer brands, DPCO risks, and high PE valuation covered.

Lupin share pros and cons: India’s pharma value play at cheap 20x PE analysed for 2026. US respiratory pipeline, FDA compliance recovery, India branded generics, and OC segment competition covered.